Clinical features and therapeutic options in non ‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF

ConclusionIn this study, concomitant mutations were found in 1.7% of the NSCLC. EGFR ‐TKI therapy was more effective than chemotherapy for patients harboringEGFR concomitant mutation, andROS1 concomitant mutations were more frequent in male patients. For patients harboring coalterations with anALK orROS1 rearrangement, we should be cautious when considering the therapeutic options.

Source: Cancer Medicine - April 23, 2019 Category: Cancer & Oncology Authors: Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou Tags: ORIGINAL RESEARCH Source Type: research